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OBJECTIVE: Here, we describe our experience with different therapeutic modalities used to treat cystic
lymphangiomas in children in our hospital, including single therapy with OK-432, bleomycin and surgery, and a
combination of the three modalities.
METHODS: We performed a retrospective, cross-sectional study including patients treated from 1998 to 2011.
The effects on macrocystic lymphangiomas and adverse reactions were evaluated. Twenty-nine children with
cystic lymphangiomas without any previous treatment were included. Under general anesthesia, patients given
sclerosing agents underwent puncture of the lesion (guided by ultrasound when necessary) and complete
aspiration of the intralesional liquid. The patients were evaluated with ultrasound and clinical examinations for
a maximum follow-up time of 4 years.
RESULTS: The proportions of patients considered cured after the first therapeutic approach were 44% in the
surgery group, 29% in the bleomycin group and 31% in the OK-432 group. These proportions were not
significantly different. Sequential treatment increased the rates of curative results to 71%, 74% and 44%,
respectively, after the final treatment, which in our case was approximately 1.5 applications per patient.
CONCLUSION: The results of this study indicate that most patients with cystic lymphangiomas do not show
complete resolution after the initial therapy, regardless of whether the therapy is surgical or involves the use of
sclerosing agents. To achieve complete resolution of the lesions, either multiple operations or a combination of
surgery and sclerotherapy must be used and should be tailored to the characteristics of each patient.
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& INTRODUCTION
Lymphangiomas (LMs) are congenital malformations that
occur in one in every 6000 births. Sixty percent of these
malformations can be observed at birth, and 80%-90% do
not arise until the patient reaches 2 years of age.
Spontaneous resolution is very rare and expectant treatment
is not recommended (1,2).
The most relevant classification system is the one that
takes into account the size of the cysts. Using this system,
lesions can be classified as macrocystic (cysts greater than
1 cm), microcystic (when most of the cysts are smaller than
1 cm), or mixed (2-7). This classification has clinical
implications because microcystic lymphangiomas appear
to be less responsive to clinical treatments such as
sclerotherapy.
Histologically, LMs are thin-walled vessels lined with
lymphatic endothelial cells, which are immunopositive for
podoplanin and lymphatic vessel endothelial hyaluronan
receptor (LYVE-1) (8-10). LMs can be empty or filled with a
serous fluid containing macrophages and lymphocytes.
Seventy to eighty percent of LMs typically occur in the
cervico-facial region; they are observed less frequently in
the axilla and thorax. The two main complications of LMs
are intralesional bleeding and infections. The best diagnostic
tool to establish a differential diagnosis with other cystic
lesions of the neck is magnetic resonance imaging (MRI),
although ultrasound (US) is commonly used to confirm the
presence of a macrocystic LM.
Classical treatment consists of surgical excision with an
attempt to preserve the nervous and vascular structures
involved. However, this is not always possible because
damage to these structures may occur during surgery and
postoperative events such as fistula formation, infection and
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wound dehiscence may develop. Surgical mortality may be
as high as 2% to 6%. Postoperative recurrence is described
in up to 27% of patients (11,12). The limitations of surgical
treatment led to the development of other forms of therapy,
such as the application of sclerosing agents (SAs) aiming to
obtain total or partial regression of the lymphangioma
(13-17).
Sclerotherapy involves entering the cystic cavity by direct
puncture, aspirating the fluid and injecting the SA. Several
sessions may be required regardless of the SA used. In our
department, we prefer to use US guidance to inject the SA.
This therapeutic modality is also not free of complications,
the most common of which are skin necrosis, local
neuropathy and, in rare cases, dose-dependent cardiopul-
monary toxicity.
Several SAs, such as ethanol, sodium tetradecyl sulfate
and doxycycline have been tested; however, the two most
extensively investigated SAs are bleomycin and OK432
(18-19).
Although published reports tend to attribute a better
sclerosing effect to OK432, the statistical significance of this
finding has not been demonstrated due to the lack of
comparative studies.
The purpose of this report is to present the results of
cervicofacial LM treatment in children using three different
therapeutic modalities in a single Brazilian institution.
& PATIENTS AND METHODS
Patients
This retrospective, descriptive, cross-sectional study
included patients treated at our hospital from 1998 to
2011. Twenty-nine children with cystic lymphangiomas
without any previous treatment were included.
The characteristics of the 29 patients included in the study
are presented in Table 1.
All patients underwent a careful clinical examination that
included measurement of the lesion and evaluation of
possible complications, such as infection or bleeding. US
was used to characterize the lesion (macrocystic in all cases)
and also to obtain a more accurate evaluation of its volume.
All the parents agreed with the proposed treatment and
postoperative evaluation. This study was approved by local
Ethics Committee (CEP: 1225/2010).
Treatment
The decision regarding what treatment the modality to
use was based on the surgeons’ preferences and the
availability of drugs in the hospital. Before 2002, surgery
was considered the initial treatment for every case of LM.
However, in more recent years, it has become preferable to
utilize SA as an initial treatment for every patient exhibiting
macrocystic lesions. Surgery has been employed mainly to
treat microcystic lesions and small lymphangiomas or as an
adjuvant therapy to remove residual lesions.
Sclerosing technique
Under general anesthesia, patients underwent puncture
of the lesion (US guided, when needed) and complete
aspiration of the intralesional liquid. Either OK-432 (equiva-
lent volume of aspirated liquid) or bleomycin (2 mg/ml
solution administered at a dose of 0.5 mg/kg) was injected
(Table 2).
The patients were evaluated postoperatively with serial
clinical examinations and US was performed in the 6th and
12th postoperative weeks. All US procedures were per-
formed by an independent radiologist who was blinded to
the medication given to each patient. If the response to
this initial therapeutic approach was considered partial or
unfavorable, then the patient was selected to receive another
dose of the same SA, to receive a dose of the other SA, or to
undergo surgery. Patients were followed up every three
months thereafter for a maximum follow-up time of up to 4
years.
Analysis
Data were collected regarding the outcome after the first
therapeutic intervention and also after completion of
treatment in the cases in which the LM did not respond to
initial therapy and the patient had to undergo further
treatment. Response to the treatment (reduction in volume),
the occurrence of adverse reactions (inflammation, infection,
necrosis) and recurrence were observed and recorded. The
response was classified as favorable (more than 90% reduc-
tion of the lesion), partial (reduction of 10% to 90% of
the lesion), or unfavorable (less than 10% reduction of the
lesion).
The primary endpoint of the study was the reduction in
lesion volume 6 and 12 weeks after treatment and the
secondary outcome was the occurrence of adverse reactions.
Due to the small number of patients included, no attempt
was made to perform any statistical analysis.
& RESULTS
The response to the initial treatment was evaluated at 6
and 12 weeks and the results are depicted in Table 3. The
proportions of patients considered cured (not needing any
further procedures) after the first therapeutic approach were
44% in the surgery group, 29% in the bleomycin group and
31% in the OK-432 group. These proportions were not
significantly different.
Sequential treatment increased the rates of curative
results to 71%, 74% and 44%, respectively, after an average
of 1.5 applications per patient (or 1.5 operations in the
surgery group) (Table 4).
Table 1 - Characteristics of the patients.
Surgery OK-432 Bleomycin Combined
Number of patients 7 9 4 9
Age (months) 24 31.3 17.75 7.2
Gender (M/F) 4/3 1/2 1/3 4/5
Size of the lesion 5.58 6.4 6.47 11.31
Location:
Cervicofacial 1 8 3 6
Axillary 2 1 1 1
Limbs 3
Trunk 1 2
Table 2 - Doses of sclerosing agents.
OK-432 Bleomycin
Diluent 0.1 KE/ml 2 mg/ml
Dose 0.1 KE/ml aspirated liquid 0.5 mg/kg
Maximal dose 2 KE/injection 5 mg/kg
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A group of nine patients received a combined treatment
that included at least two of the treatment modalities. The
success rate in this group of patients was 44%.
At this point in the evaluation, when considering all of the
therapeutic modalities, 56% of the patients are considered
cured, whereas 44% have persistent or residual lesions and
are awaiting further therapy.
Complications
There were two instances of serious surgical complica-
tions involving injury to the hypopharynx in one case and
injury to the carotid artery in another case. These complica-
tions were detected and promptly treated during the
operation. No complications were associated with the use
of OK-432 or bleomycin.
& DISCUSSION
Bleomycin was first described as anti-tumor agent that
functioned by inhibiting DNA synthesis in 1966 (20). Later,
this drug was also shown to have an effect on sclerosing
endothelial cells via a non-specific inflammatory reaction. In
1977 (21), bleomycin was used for the first time as an SA in
lymphangioma. For better control and targeting of the drug,
it was used in the form of microspheres in an oil emulsion
in 1987 (22). The side effects of bleomycin sclerotherapy
are described as minimal, aside from local swelling and
inflammation. The most feared complication is pulmonary
fibrosis, which has been reported when bleomycin is
administered as chemotherapy for cancer in a much higher
cumulative dose (450 mg) (23,24). For sclerotherapy of
hygroma, previous authors have suggested a dose of less
than 1 mg/kg for a duration of 2 weeks or more, with a total
dose of 5 mg/kg (14).
OK-432, produced by lyophilization of Streptococcus
pyogenes group A strains with low virulence that were
treated in culture with penicillin G potassium, has also
been used with favorable results (4,5,13,17). OK-432 was
approved by the Japanese Ministry of Health for use as a
biological response modifier. It was first used in clinical
trials for the treatment of head and neck cancers in 1987;
since then, it has been used in the treatment of lymphan-
gioma (25) in 22 countries, including Japan. In Brazil, the
use of OK-432 was approved by the Brazilian National
Agency of Sanitary Control-ANVISA (26) in February 2009.
The clinical effect of OK-432 occurs via damage to the
endothelium of lymphangiomas secondary to activation of
the immune system. It has been demonstrated, both in vitro
and in vivo, that OK-432 promotes the induction and
augmentation of activated macrophages, NK cells and
LAK cytotoxic T lymphocytes. Sclerosis is confined to the
interior of the cysts without damaging the surrounding
tissue. Due to this mode of action, the use of OK-432 does
not appear to increase the difficulty of a subsequent
operation to remove any residual lesion (9).
The most complete review of the literature comparing
bleomycin with OK-432 was a meta-analysis performed in
2008 (16). The authors selected 22 papers reporting large
series but could only find one prospective randomized
study. The conclusions of this meta-analysis were as
follows: OK-432 showed a tendency to be a better SA than
bleomycin; however, there was no statistically significant
difference between OK-432 and bleomycin. Seven serious
complications occurred in seven different studies and two
children died from pulmonary complications in the groups
treated with bleomycin; however, a direct cause-effect
relationship could not be demonstrated. Sclerotherapy
appears safe; however, a small number of patients have
developed acute respiratory failure requiring tracheostomy,
regardless of the SA used. Apparently, this event is
associated with the presence of bulky lymphangiomas
possibly invading the chest.
Despite the low number of applications (average of 1.55
per patient), there were no unfavorable results among the
patients receiving OK-432 as the sole therapy (Table 1),
meaning that all patients have displayed at least a partial
response. However, it should be noted that only 4 patients
have reached complete remission of the lesion, whereas 5
are still under treatment and should receive additional
treatment with OK-432 until they are considered cured.
Data from the literature indicate that as many as 5
applications may be needed to achieve complete resolution.
Additionally, in the bleomycin group, 3 out of 4 patients
have shown a favorable response to treatment after one or
two applications.
In our small sample, bleomycin did not lead to systemic
complications, especially the most feared (in the case of
overdose): pulmonary fibrosis.
Overall, forty-four percent of our patients are still waiting
for some type of therapy (34% with partial results, 10% with
poor results).
As previously stated, surgery was previously the first-line
therapy for all lymphangiomas. With the introduction of
sclerotherapy, surgical excision is now reserved either for
the resection of remaining fibrotic tissue after sclerotherapy
or, after an informed joint decision with the family, as a
first-line therapy for lymphangiomas localized outside the
cervicofacial region, where the risk of injuring nervous
structures is smaller and the resulting scars less important
from an aesthetic point of view.
Table 3 - Use of surgery or injection as the initial
procedure in each patient.
Surgery Bleomycin OK-432 TOTAL
Favorable 4 (44%) 2 (29%) 4 (31%) 10 (34%)
Partial 3 (33%) 4 (57%) 9 (69%) 16 (55%)
Unfavorable 2 (22%) 1 (14%) 0 3 (10%)
TOTAL 9 7 13 29
Table 4 - Final response to treatment.
Surgery Bleomycin OK-432 Combined TOTAL
Favorable 5 (71%) 3 (75%) 4 (44%) 4 (44%) 16 (56%)
Partial 1 (14%) 0 5 (56%) 4 (44%) 10 (34%)
Unfavorable 1 (14%) 1 (25%) 0 1 (11%) 3 (10%)
TOTAL 7 4 9 9 29
Average number of surgeries/applications 1.57 1.5 1.55 3 2
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The groups that included surgery as a therapeutic
modality were the ones with a higher rate of poor outcome
(surgery and combined groups). The less favorable results
observed in patients undergoing surgery, especially in the
cervicofacial region, may be attributed to the efforts to spare
the neural and vascular structures that cross this anatomic
region, which very often precludes the complete resection of
this malformation. Overall, we encountered two serious
intraoperative complications (one carotid lesion and one
lesion of the hypopharynx) that were promptly corrected in
the same operation.
In conclusion, despite the limitations inherent in a
retrospective study including a small number of patients,
the results of this study indicate that most patients with
cystic lymphangiomas do not show complete resolution
after initial therapy, regardless of whether the therapy is
surgical or involves the use of SAs. To achieve complete
resolution of the lesions, either multiple operations or a
combination of surgery and sclerotherapy must be used and
should be tailored to the characteristics of each patient.
Although the number of patients is too small to draw any
definitive conclusions, no single sclerosing agent showed
superiority over the other agents. Prospective randomized
clinical trials should be designed to investigate this issue.
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